

Foundations to Practice: Pathophysiology of Cancer, Cancer Treatment Modalities, and the Immune System

Monday, August 29th, 2022

UPMC Shadyside Herberman Conference Center Room 201AB and Remote Attendance

Learning Objectives

The learner will be able to:

1. Identify the role of the Foundations to Practice Series in providing care to patients with cancer.
2. Recognize characteristics of malignant disease.
3. Describe the meaning of cancer disparity.
4. Explain the role of different treatment modalities in treating patients with cancer.
5. Recall the immune system's function in the development and treatment of cancer.
6. Identify goals of treatment for patients with cancer.
7. Recognize the role of clinical trials in treating patients with cancer.
8. Demonstrate learning has occurred by receiving at least an 85% on the final knowledge assessment.

Contact Hours

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Pittsburgh has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 7 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

The maximum number of hours awarded for this Continuing Nursing Education activity is 7 contact hours.

To receive 7 Contact Hours, the learner must sign in, attend the entire activity, complete the activity evaluation, and achieve $\geq 85\%$ on the knowledge assessment. Attendance will be tracked throughout the day of the course.

Schedule

7:30 am	Registration (Live) and TEAMS Login	
8:00 am	Welcome and Introduction to Foundations to Practice Series	Amy DiMaggio, MSN, RN, CMSRN, OCN
8:10 am	Pathophysiology of Cancer	Brittni Prosdocimo, MSN, RN, BMTCN
9:05 am	The Immune System and Immunotherapy	Melissa Wilson, PA-C
9:40 am	Cancer Disparities	Lyn Robertson, DrPH, MSN, RN
10:20 am	Break	
10:30 am	Evaluating Complementary Therapies	Lyn Robertson, DrPH, MSN, RN
11:15 am	Stem Cell Transplant and CAR T-Cell Therapy	Brittni Prosdocimo, MSN, RN, BMTCN
11:50 am	Lunch	
12:30 pm	Chemotherapy, Hormonal Therapy, and Biotherapy	Shrina Duggal, PharmD, BCOP
1:25 pm	Goals of Treatment and Treating on Time	Ketura Miller, BSN, RN, OCN
1:55 pm	Break	
2:05 pm	Clinical Trials	Jennifer Ruth, BSN, RN, CCRP
2:40 pm	Radiation Therapy	Christopher Maney, BSN, ADN, RN, OCN
3:20 pm	Surgery	Elizabeth Lacey BSN, RN, OCN
3:55 pm	Course Review	Amy DiMaggio, MSN, RN, CMSRN, OCN
4:00 pm	Adjournment	

Faculty Listing

*Shrina Duggal, PharmD, BCOP
Clinical Oncology Pharmacy
Program Manager
UPMC Hillman Cancer Center*

*Elizabeth Lacey BSN, RN, OCN
Professional Staff Nurse
UPMC Hillman Cancer Center*

*Christopher Maney, BSN, ADN,
RN, OCN
Senior Professional Staff Nurse ,
Radiation Oncology
UPMC Hillman Cancer Center,
Central PA Region*

*Ketura Miller, BSN, RN, OCN
Nurse Navigator
UPMC Hillman Cancer Center,
Pinnacle*

*Brittini Prosdocimo, MSN, RN,
BMTCN
Advanced Clinical Education
Specialist
UPMC Hillman Cancer Center*

*Lyn B. Robertson, DrPH, MSN, RN
Assistant Professor of Medicine
Associate Director for Health
Equity and Community Outreach
and Engagement
UPMC Hillman Cancer Center*

*Jennifer Ruth, BSN, RN, CCRP
Clinical Research Manager
UPMC Hillman Cancer Center*

*Melissa Wilson, PA-C
Physician Assistant, Senior
UPMC Hillman Cancer Center*

Disclosure of Conflicts of Interest

All individuals in a position to control the content of this education activity are required to disclose all relevant financial relationships with any proprietary entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by patients.

The following information was provided: Elizabeth Lacey, Christopher Maney, Ketura Miller, Brittini Prosdocimo, Lyn Robertson, Jennifer Ruth, Melissa Wilson, and the planning committee for this activity did not have any relevant financial relationships with a commercial interest.

Shrina Duggal has disclosed the following conflicts: CE Speakers' Bureau for Incyte, Astellas, and Pfizer; Consultant for UpToDate.